Showing results (661-670 of 1,126) with videos related to
Sort By:
Pageof 113
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1995
[Role of pharmacist in cancer pain management]S Yoshida, Y Akagi, E Horiuchi, et al.British Journal of Cancer|January 1, 1996
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerI Adachi, T Watanabe, S Takashima, et al.Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|June 1, 1996
[A fulminating case of Edwardsiella tarda septicemia with necrotizing fasciitis]S Matsushima, S Yajima, T Taguchi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 3, 1998
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)]T Taguchi, Y Sakata, R Kanamaru, et al.Biochemistry|March 4, 2015
Redox potential tuning through differential quinone binding in the photosynthetic reaction center of Rhodobacter sphaeroidesJosh V Vermaas, Alexander T Taguchi, Sergei A Dikanov, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1987
[Damaging action of human recombinant TNF on tumor vessels as an aspect of its anti-neoplastic action against Meth A sarcoma in mice]H Nakamura, S Motoyoshi, Y Seto, et al.International Journal of Oncology|August 9, 2001
Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapyK Kasahara, T Taguchi, I Yamasaki, et al.Cancer Genetics and Cytogenetics|August 16, 2000
Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: fluorescence in situ hybridization analysis of 5 Japanese casesT Karashima, T Taguchi, C Yoshikawa, et al.The Journal of Antimicrobial Chemotherapy|August 10, 2000
Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin BM A Hossain, S Maesaki, M S Razzaque, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1994
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri]K Noda, Y Terajima, Y Ogita, et al.Pageof 113